Nov 11, 2026, 14:55 by ASAM Weekly Editors

Online sports betting legalization and mental health care use, opioid use disorder medication access in residential treatment, polysubstance use on urine drug testing, MOUD gaps in pregnancy care, and alcohol withdrawal treatment outcomes.

Nov 11, 2026, 13:47 by Sarah Shelson

CMS's 2027 payment changes will not affect all addiction medicine practices equally.

Nov 10, 2026, 08:38 by Sarah Shelson

The American Society of Addiction Medicine (ASAM) today released its first clinical guidance for managing intoxication and withdrawal involving medetomidine, an emerging adulterant in the unregulated opioid supply linked to unique and severe symptoms.

Nov 3, 2026, 17:20 by ASAM Weekly Editors

Methylphenidate trial design for cocaine use disorder with comorbid ADHD, alcohol screening and treatment referral gaps, nonfatal overdose and naloxone trends, medication awareness for alcohol use disorder, and jail-based opioid treatment lessons.

Nov 3, 2026, 10:08 by Cathy Lease

Letizia Biso, MD, and Marco Scarselli, PhD, propose that while methylphenidate has not been shown to significantly reduce craving or cocaine use in patients with cocaine use disorder (CUD), it may benefit patients with comorbid CUD and ADHD. Explore why clinical trials evaluating methylphenidate for cocaine use disorder must rethink study designs around comorbid ADHD to improve treatment outcomes.

Oct 28, 2026, 12:35 by Sarah Shelson

Collaboration brings ASAM’s clinical guidelines and implementation resources to the point of care for the millions of clinicians who use OpenEvidence

Oct 27, 2026, 18:49 by ASAM Weekly Editors

Stimulant treatment for comorbid ADHD and SUD, climate-related disasters and addiction care, heroin overdose risk profiles, urine drug testing and MOUD linkage, and declining benzodiazepine dispensing.

Oct 27, 2026, 12:39 by R. Corey Waller, MD, MS, FACEP, DFASAM

Dr. Jenna L. Butner and Emma Biegacki discuss how climate-related events disrupt access to substance use disorder prevention, treatment, and harm-reduction services. They call for greater preparedness through research, advocacy and legislation, and education and training.

Oct 21, 2026, 10:48 by ASAM Weekly Editors

Harm reduction under political pressure, projected outcomes for people who inject drugs, methadone travel barriers, medetomidine withdrawal protocols, and ketamine and stimulant treatment coverage.

Oct 20, 2026, 10:19 by R. Corey Waller, MD, MS, FACEP, DFASAM

Dr. Jessica Gregg, FASAM, examines the distinction between harm reduction interventions and unsheltered encampments, and argues for evidence-based policies that address root causes of homelessness.

Oct 14, 2026, 10:42 by ASAM Weekly Editors

Psilocybin use and unmet mental health treatment needs, buprenorphine in the emergency department, postpartum overdose risk with MOUD, alcohol-associated liver disease medication trends, NLP in couples therapy, and cannabis and sleep

Oct 7, 2026, 12:40 by Sarah Shelson

ASAM, the AMA, and eight other medical societies have filed an amicus brief in support of litigation challenging CMS’ interim final rule implementing Medicaid work requirements. The groups argue that their most vulnerable patients are at risk of losing Medicaid coverage if unlawful parts of CMS’ interim final rule go into effect.

Oct 6, 2026, 19:09 by ASAM Weekly Editors

Cannabis use disorder rising among older adults, medetomidine withdrawal driving ICU admissions, opioid settlement fund oversight gaps, gambling comorbidity in SUD treatment, and the polygenic architecture of tobacco use disorder.

Sep 29, 2026, 19:56 by ASAM Weekly Editors

Cannabis use disorder rising in California adolescents post-legalization, cannabinoid hyperemesis syndrome review, ADHD and elevated SUD risk, buprenorphine access and child welfare outcomes, and GLP-1 agonists for alcohol use disorder.

Sep 23, 2026, 13:44 by ASAM Weekly Editors

Buprenorphine discontinuation challenges with 1 in 3 prescriptions abandoned, fentanyl-stimulant co-use risks, opioid-sedative co-use patterns, oral nicotine pouch trends in adolescents, and FDA hearing on psychedelics.

Sep 18, 2026, 15:03 by Sarah Shelson

The Pennsylvania Society of Addiction Medicine endorsed legislation that would regulate kratom in the state.

Sep 17, 2026, 13:56 by Sarah Shelson

ASAM is urging CMS to support access to addiction care by increasing payment for key prevention and treatment services.

Sep 16, 2026, 11:40 by ASAM Weekly Editors

Stimulant-only overdose deaths rising amid opioid decline, care navigation for methamphetamine use disorder, cannabis detected in 21% of overdose deaths, prescription cannabis use disorder, adolescent polysubstance co-use and dosing, Addiction Consult Services reducing readmissions, prenatal alcohol exposure and brain maturation, and youth substance use ED visits.

Sep 16, 2026, 09:47 by Sarah Shelson

The American Society of Addiction Medicine (ASAM) has sent a letter to Congressional leaders urging them to pass the bipartisan Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) before the end of the year.

Sep 9, 2026, 11:03 by ASAM Weekly Editors

Fatal overdose isolation patterns from SUDORS 2022–2024, police drug market disruptions and overdose risk in San Francisco, medetomidine emergence in Philadelphia, methadone versus buprenorphine survival after nonfatal overdose, expanding alcohol screening to reduce premature mortality, unauthorized e-cigarette market dominance, and ADAPT for adolescent SUD treatment.